Natera Q4 2021 Earnings Investor Presentation

Natera reported strong 2021 results with 1.57M tests processed and $625.5M revenue (+60% YoY), alongside landmark clinical achievements including the CIRCULATE-Japan study validating Signatera MRD for colorectal cancer and publication of the SMART 22q11.2 deletion trial. The company guided 2022 revenue of $770-790M, reflecting continued momentum in its non-invasive prenatal testing and oncology diagnostics businesses.